Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

mong existing oral OAB treatments, according to Dr. Sand. "Watson's oxybutynin gel is an elegant topical formulation that is clear, odorless and fast drying and will offer healthcare providers a unique treatment option for OAB patients," said Dr. Sand.

The Phase 3 multi-center, double blind, placebo-controlled study evaluated the efficacy and safety of OTG in 789 patients with overactive bladder. The primary objective of the study was to demonstrate that daily treatment of a 1g dose (approximately 1 mL) of OTG for 12 weeks was superior to placebo for the relief of OAB symptoms. Changes from baseline to endpoint were calculated from a three-day patient urinary diary and included a reduction in incontinence episodes and urinary frequency, and an increase in void volume. Additionally, 216 patients participated in a 14-week, open label, safety-extension study for a total of 26 weeks. During the double-blind portion of the trial, highly statistically significant improvements relative to placebo were seen on all of these endpoints.

Secondary endpoints also included a patient assessment of incontinence-specific, quality-of-life measures using multiple validated instruments including the Incontinence Impact Questionnaire (IIQ) and the King's Health Questionnaire, which indicated a significant positive effect of OTG treatment on quality-of-life total and subscale scores at endpoint in comparison with placebo.

OTG was well tolerated in the study. No serious adverse events related to the treatment were reported. Dry mouth (6.9%) and application site pruritis (2.1%) were the only treatment-related side effects reported at levels greater than 2%. Treatment-related adverse events that resulted in study discontinuation during the double-blind period were low (1.8%) and the similar for both the treatment and placebo groups.

Phase 1 studies have demonstrated that the steady-state plasma levels of oxybutynin show little fluctuation during the 24-hour dosin
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Pressure ... "Company") and Parabase Genomics ("Parabase"), (together "the ... a strategic research and development agreement (the ... PBI will develop a front-end, sample preparation ... and newborn confirmatory testing process. The sample ...
(Date:7/22/2014)... July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... commercialization of its non-invasive Monarch ™ eTNS™ ... disorders, today announced that enrollment has begun in a ... (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut ... at the Olive View-UCLA Medical Center in ...
(Date:7/22/2014)... , July 22, 2014 ... umfassenden Schutz von Pharmazeuten und Krankenpflegern ... Equashield ( http://www.equashield.com ), ... System Transfer Devices, CSTDs) für gefährliche Medikamente, ernannte ... und Hersteller von medizinischen Produkten, zu seinem ...
Breaking Medicine Technology:Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Turn the Tide on Antibiotic-Resistant InfectionsPRINCETON, N.J., March ... and the Plexus Institute (Plexus) today announce results ... Staphylococcus aureus (MRSA) prevention program that employed ... and behavioral change, to trigger significant reductions in ...
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
Cached Medicine Technology:CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 2CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 3CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5
(Date:7/22/2014)... (PRWEB) July 22, 2014 DocbookMD ... process of deploying one of the largest physician-centric mobile ... ( MHMD ) in Houston. , Created by Austin-based ... the DocbookMD application will be embedded into MHMD’s Accountable ... searched for the best technology to put this capability ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Dr. Dental is ... existing patients and new visitors in mind, one of the ... and visual layout that makes navigation very easy. Dr. Dental ... experience of going to the dentist affordable, convenient and fun, ... helpful new feature is an appointment scheduling system right on ...
(Date:7/22/2014)... 22, 2014 A Florida woman has ... that alleges the death of her husband was the ... thinner, Bernstein Liebhard LLP reports. According to her complaint, ... for the Southern District of Florida on June 23rd, ... suffered a subdural hemorrhage the following June. Despite emergency ...
(Date:7/22/2014)... Among women undergoing a minimally invasive hysterectomy using electric ... 10,000 women at the time of the procedure, according ... has been concern that this procedure, in which the ... the spread of undetected malignancies. , Despite the commercial ... estimates of the prevalence of malignancy at the time ...
(Date:7/22/2014)... July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014”) championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). , ...
Breaking Medicine News(10 mins):Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 4Health News:Dr. Dental Reveals Exciting New Website 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... , ... ... ... ...
... Research (AADR) has announced David C. Johnsen, dean of the ... the 2010 AADR Jack Hein Public Service Award. This award ... Meeting & Exhibition in Washington, DC, March 3, 2010. ... Institutes of Health and the National Institute of Dental and ...
... American Association for Dental Research (AADR) has announced Irwin D. ... York, as the recipient of the inaugural 2010 AADR Distinguished ... Annual Meeting & Exhibition in Washington, DC, March 3, 2010. ... in 1946, and gave up his part-time private practice in ...
... study suggests , FRIDAY, Feb. 19 (HealthDay News) -- In ... have identified a defective signaling pathway that contributes to the ... thick, sticky mucus to build up in the lungs and ... lethal genetic diseases in children and young adults. , In ...
... ... ... ... ...
... ... in the Ambulatory EHR space , ... (PRWEB) February 19, 2010 -- CapSite™ has announced the release of the 2010 U.S. ... the Health Information Technology for Economic and Clinical Health (HITECH) component of the American Recovery ...
Cached Medicine News:Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 2Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 3Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 4Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 5Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 6Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 7Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 8Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:CapSite Announces Release of the 2010 U.S. Ambulatory EHR Study 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: